BriaCell Therapeutics (NASDAQ:BCTX) Releases Earnings Results, Misses Estimates By $0.14 EPS

BriaCell Therapeutics (NASDAQ:BCTXGet Free Report) released its earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14), Zacks reports.

BriaCell Therapeutics Trading Up 6.2 %

NASDAQ BCTX opened at $0.65 on Wednesday. BriaCell Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.97. The company’s 50-day moving average price is $0.82 and its 200-day moving average price is $0.86. The stock has a market cap of $23.36 million, a PE ratio of -0.55 and a beta of 1.46.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, December 12th.

Read Our Latest Report on BCTX

About BriaCell Therapeutics

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.

Further Reading

Earnings History for BriaCell Therapeutics (NASDAQ:BCTX)

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.